Rahul Kumar
@kumarrahul0204
Followers
505
Following
7K
Media
26
Statuses
11K
It’s all about the Journey never the destination. Director, Hepatology Services, CGH Singapore. Asst Prof Duke-NUS Graduate Medical School.
Singapore
Joined January 2010
At the Bengal Liver Summit 2026, our ALF session dives deep into the intricacies of acute liver failure — cutting-edge insights, challenges of CRRT and PLEX and forward-looking management. Join us as we decode ALF together! https://t.co/X1Tc38RBhy
0
2
9
Stigma & fatigue remain less commonly addressed issues in managing patients with IBD...Check out articles addressing the same with @DrAnuraagJ @drpreetamnath @drvishal82 @AKSHAYK49225783 @hsid_h Stigma in IBD: https://t.co/eFCoxo0Kl4 Fatigue in IBD: https://t.co/sKepIdutRR
2
20
46
Abstract Submission ➕ Registrations Now Open 📂 https://t.co/X1Tc38RBhy
@ajay_duseja
@AnandVKulkarni2 @docMPK @drnipunverma @drsuniltaneja @DrKaushalMadan1 @doc_arka @DrAshish_Kumar @kumarrahul0204 @ebtapper @JasmohanBajaj @RajivJalan1 @DrHuangDQ @RobertFontanaMD
bls2026.com
Last date of abstract submission being 14th December 2025. Count Every Second Until The Event Days Hours Minutes Seconds We Look Forward To WELCOMING YOU TO KOLKATA Dear Colleagues, It is a great...
🪔On this auspicious occasion of Diwali We are thrilled to announce the Bengal Liver Summit 2026! 📅 8–10 January 2026 📍 ITC Royal Bengal, Kolkata 🎯 Theme: Acute Complications in Liver Disease 🌍 12 International 🇮🇳 100+ National Faculties Stay tuned for more updates! #BLS2026
1
6
23
📴📰CRRT in Acute Liver Failure - Rationale,Evidence,Practice -Beyond Kidneys -Real world issues With @AnandVKulkarni2
@ajay_duseja @docMPK @MaiwallRakhi @drnipunverma @drshalimar @RobertFontanaMD @ebtapper @RohitMehtaniDM @JasmohanBajaj 👇🏽Check out now
jcehepatology.com
Acute liver failure (ALF) is a life-threatening condition hallmarked by an acute onset of liver dysfunction, coagulopathy, and encephalopathy in individuals without pre-existing liver disease....
3
14
32
🚨 New editorial alert! Explores how AI is reshaping liver failure prognosis in critically ill cirrhosis 🔍 Explainable AI | 🧠 Clinical insight | ⚖️ Better outcomes @JustSagnik 👇🏽 https://t.co/CeL6rkCjgK Original 📃👇🏽 https://t.co/YGObGKpegl
@drnipunverma
2
4
15
🪔On this auspicious occasion of Diwali We are thrilled to announce the Bengal Liver Summit 2026! 📅 8–10 January 2026 📍 ITC Royal Bengal, Kolkata 🎯 Theme: Acute Complications in Liver Disease 🌍 12 International 🇮🇳 100+ National Faculties Stay tuned for more updates! #BLS2026
2
8
24
https://t.co/gD17oeOMXN ROTEM based transfusion strategy reduced prophylactic blood product transfusion for PLEX port insertion among ALF and ACLF patients @cmcvelloreoff @OffCMCVellore @joy_mammen
2
8
16
Advance Hepatology with JCEH 📊 Impact Factor: 3.2 📈 CiteScore: 5.1 ⏱️ Editorial decision: ~4.9 days ⚡ Online publication: ~4.9 days post-acceptance 📢 Now inviting high-impact liver research. 📝 Submit today 👇🏽 https://t.co/2E4qyL96mQ
@AnandVKulkarni2 @docMPK @ajay_duseja
1
11
27
📜Just published in JCEH! Stool urease activity (SUA) better predicts OHE than NH3 📈 SUA linked to gut 🦠 activity & hyperammonemia. 🧫 ?novel biomarker for early OHE risk @ILBS_India
@drshivsarin @drnipunverma @AnandVKulkarni2 @drshalimar @kumarrahul0204
0
5
15
📢Autoantibodies matter in #MASLD Global study of 460 biopsy-proven cases, ANA or ASMA positivity independently predicted: ⚠️ 3.9× higher risk of liver decomp ⚰️ 2.5× higher risk of death 📉 Histologic AIH features didn’t correlate with outcomes 👉 https://t.co/kxeEaeoVI1
1
25
61
New @JCEH_Hepatology 🚨 🕐-restricted eating (TRE) supercharges insulin sensitivity in MASLD! 🥗⏰🔥 📊 TRE+Hypocaloric(HCD) vs HCD 🩺 HOMA-IR drop 2.6(TRE+HCD) vs 1.5(HCD) 🛠️ Steatosis 66.7% (TRE+HCD) vs 52.4%(HCD) @ajay_duseja @doc_arka @DrAshish_Kumar
1
3
8
🚨 New 📜 @JCEH_Hepatology 270 LT patients ⏭️13 years 🫀 Coronary CTA identified CAD in 70% 💀 ⬆️ CAD-RADS - 📈 mortality ❌ CAC score did NOT ❤️ CAD-RADS 0–1 :0️⃣ MIs 👉 Coronary CTA 💪🏽 @LiverFellow
@_LTSI_ @INASL_Liver @_ILTS_
@RohitMehtaniDM @docMPK
jcehepatology.com
Cardiovascular risk stratification is crucial in patients with end-stage liver disease (ESLD) yet the optimal noninvasive strategy remains debated. Our study aimed to assess the prognostic value of...
0
2
5
Amazing work congratulations
🚨 Just out in @HEP_Journal From 🌍 POCUS👸🏽 @docMPK POCUS 🎯volume management in AKI 💔 CCM 🔑determinant of outcomes 🔸3/4 with HRS have it 🧠 Dynamic, tailored 💦strategy improves AKI 📉 CCM = 8.9× ↑ ⚰️ @AnandVKulkarni2 @drnipunverma @ajay_duseja ⏬
0
0
0
The passing of Prof. Jaume Bosch (1947–2025) has generated, and continues to generate, heartfelt tributes Here you can read some of them: Scientific societies 🇪🇺EASL: https://t.co/v4Oz8jwAKF 🇪🇸AEEH: https://t.co/bW7fW0EzPB 🇨🇭SASL: https://t.co/gRSTJ3QWUN
3
9
56
📕Editorial @hartl_md @MedUni_Wien in the Journal of Clinical and Expertimental Hepatology Revisiting the Role of Transjugular Transhepatic Portosystemic Shunt (#TIPS) for Portal Vein Recanalization #PVRTIPS in #Cirrhosis w Portal Vein Thrombosis #PVT 🔗 https://t.co/3GBE2zkCHS
2
13
25
INASL-2025 Chandigarh- 7-10th August, 2025 INASL-EASL-AASLD Joint Symposium on ALD 9th August, 2025 Register Now- https://t.co/wncBDReZVM
@drsuniltaneja @docMPK @drnipunverma @doc_arka @naveendandia @drbabupgi @AleksanderKrag
@DebbieShawcros1
@AASLDtweets
@EASLnews
@GSzaboMD
INASL-2025 7th - 10th August, 2025 Chandigarh INASL-EASL-AASLD Joint Symposium on Alcohol Related Liver Disease (ALD) Saturday, 9th August, 2025
0
5
15
One of the saddest days for hepatology community at large. All the emotional strength to you @docberza to bear this unimaginable loss. He will forever live and be remembered for the quality of work he produced and the hepatologists he nurtured 🙏.
REMEMBERING Professor JAUME BOSCH (@jaumebosch9) President of Baveno @BavenoCoop Friend and Mentor to many
0
0
2
Rest in peace Professor Bosch 🙏
Ciao Jaume, goodbye cariño mio. You have been such a special and wonderful man and I will love you forever.
0
0
2